Holen Sie sich die Stockscreener-App
14.73
0.68%
0.10
Handel nachbörslich:
14.50
-0.23
-1.56%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt RDY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$14.63
Offen:
$14.67
24-Stunden-Volumen:
552.38K
Relative Volume:
0.45
Marktkapitalisierung:
$12.30B
Einnahmen:
$3.85B
Nettoeinkommen (Verlust:
$667.93M
KGV:
22.42
EPS:
0.657
Netto-Cashflow:
$142.30M
1W Leistung:
+1.03%
1M Leistung:
+3.59%
6M Leistung:
+16.17%
1J Leistung:
-7.57%
1-Tages-Spanne:
$14.67
$14.77
1-Wochen-Bereich:
$14.54
$14.85
52-Wochen-Spanne:
$12.26
$16.19
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Vergleichen Sie RDY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
14.73 | 12.18B | 3.85B | 667.93M | 142.30M | 0.657 |
|
ZTS
Zoetis Inc
|
147.46 | 64.82B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.12 | 47.56B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.28 | 43.31B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.68 | 21.67B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
397.97 | 18.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-12-19 | Herabstufung | Nomura | Buy → Neutral |
| 2024-01-11 | Herabstufung | Jefferies | Buy → Underperform |
| 2023-08-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-05-18 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-30 | Eingeleitet | JP Morgan | Underweight |
| 2022-11-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Fortgesetzt | BofA Securities | Neutral |
| 2021-07-27 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-09-18 | Hochstufung | Investec | Sell → Hold |
| 2020-01-28 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-27 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-09 | Hochstufung | Citigroup | Sell → Buy |
| 2019-11-04 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Hochstufung | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Hochstufung | Macquarie | Neutral → Outperform |
| 2019-06-20 | Eingeleitet | Deutsche Bank | Hold |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Hochstufung | CLSA | Outperform → Buy |
| 2019-01-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2017-09-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Hochstufung | CLSA | Underperform → Outperform |
| 2017-07-28 | Herabstufung | CLSA | Underperform → Sell |
| 2016-07-27 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Herabstufung | Jefferies | Hold → Underperform |
| 2016-02-10 | Hochstufung | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Dr Reddys Laboratories Ltd Adr Aktie (RDY) Neueste Nachrichten
Asian ADR Index Edges Up As LG Display Leads - Finimize
Dr. Reddy’s Laboratories Allots Equity Shares Under Employee Stock Option Scheme - TipRanks
Dr Reddy's shares fall as USFDA flags Hyderabad plant with 5 observations - Business Standard
Asian ADRs Gain As Investors Show Renewed Interest - Finimize
Asian Equities In The US Logged Broad Gains This Session - Finimize
Mixed Performance For Asian Stocks Traded In The US - Finimize
Dr. Reddy’s Laboratories Allots Equity Shares to Employees - TipRanks
Invesco Ltd. Has $8.12 Million Stake in ATRenew Inc. Sponsored ADR $RERE - Defense World
Validea's Top Health Care Stocks Based On Peter Lynch8/25/2025 - Nasdaq
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Barchart.com
National Bank of Canada FI Boosts Stock Position in Dr. Reddy's Laboratories Ltd $RDY - MarketBeat
Asian ADRs Trade Lower As S&P Asia 50 Index Drops - Finimize
Asian Tech Names Lift US-Traded Stocks To A Small Gain - Finimize
LLY Stock Quote Price and Forecast - CNN
Dr. Reddy’s Subsidiary Imperial Dissolved Following NCLT Approval - TipRanks
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 50% Tariff On India - MSN
Asian Stocks In The US See Mixed Moves Across Sectors - Finimize
Trump hikes tariffs on India by additional 25% citing Russian oil trade; iShares India ETF, ADRs react - Moneycontrol
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT - GlobeNewswire Inc.
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
Dr Reddys Laboratories Faces Continued Stock Decline Amid Broader Market Challenges - Markets Mojo
Asian ADRs Falter On US Markets As Fintechs Slide - Finimize
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 25% Tariff On India - MSN
NVO Stock Quote Price and Forecast - CNN
Asian Stocks Listed In The US Kicked Off The Week Lower - Finimize
Asian Stocks Dipped As US-Listed ADRs Edged Lower - Finimize
From Infosys, IndusInd Bank to Natco Pharma, 9 stocks to watch today - financialexpress.com
Stock Picks Today: Infosys, Dr. Reddys Labs, Kajaria Ceramics, Tata Consumer Products On Brokerages Radar - NDTV Profit
Asian Stocks Mixed As S&P Asia 50 ADR Index Falls - Finimize
Dr Reddy's Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - MSN
Dr. Reddy’s Labs ADR earnings missed, revenue fell short of estimates - Investing.com Australia
India's Dr Reddy's says open to boosting U.S. manufacturing as tariff threat looms - sg.finance.yahoo.com
Finanzdaten der Dr Reddys Laboratories Ltd Adr-Aktie (RDY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):